SPINK4 modulates inhibition of glycolysis against colorectal cancer progression

Xiaodi Yang1, Sen Jiang2, Zhen Yuan1

  • 1Department of Oncology, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Whole-period Monitoring and Precise Intervention of Digestive Cancer (SMHC), Minhang Hospital and AHS, Fudan University, Shanghai, China.

PubMed

Insights

Serine peptidase inhibitor, Kazal type 4 (SPINK4) is downregulated in colorectal cancer (CRC), inhibiting tumor growth and proliferation. SPINK4 acts as a key inhibitor of glycolytic metabolism, offering potential for CRC metabolic intervention.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Glycolysis dysregulation is linked to aggressive colorectal cancer (CRC) tumor activity.
  • Serine peptidase inhibitor, Kazal type 4 (SPINK4) is associated with CRC, but its role in glycolysis and gene expression is unclear.

Purpose of the Study:

  • To investigate the role of SPINK4 in colorectal cancer (CRC) progression, focusing on its impact on glycolysis, cell cycle, and apoptosis.
  • To analyze SPINK4 expression and its correlation with patient prognosis in CRC.

Main Methods:

  • Bioinformatic analysis of CRC datasets (GSE32323, GSE141174) to screen differentially expressed genes (DEGs) and analyze SPINK4 expression and prognosis.
  • In vitro studies using flow cytometry, western blotting, transwell assays, and qRT-PCR to assess SPINK4's effects on CRC cell proliferation, invasion, migration, apoptosis, cell cycle, and glycolysis.
  • In vivo xenograft models and histological/immunohistochemical analyses to evaluate SPINK4's impact on tumor development and expression patterns in CRC tissues.

Main Results:

  • SPINK4 expression was found to be downregulated in CRC tissues and correlated with poor patient prognosis.
  • SPINK4 overexpression inhibited CRC cell proliferation, invasion, and migration, induced G1 arrest, and promoted apoptosis.
  • SPINK4 overexpression reduced glycolytic activity, 2-Deoxy-D-glucose (2-DG) absorption, and modulated key glycolytic enzymes (HK2, GLUT1, LDHA, PKM2), significantly reducing tumor volume in vivo.
  • SPINK4 knockdown reversed these effects, promoting CRC progression.

Conclusions:

  • SPINK4 acts as a tumor suppressor in colorectal cancer by inhibiting proliferation, invasion, migration, and glycolysis.
  • SPINK4's downregulation in CRC suggests its potential as a prognostic biomarker.
  • SPINK4's role as a key inhibitor of glycolytic metabolism presents therapeutic opportunities for CRC intervention.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Gene Regulation During Sporulation01:17

Gene Regulation During Sporulation

Sporulation is a complex developmental process that allows certain Gram-positive bacteria, such as Bacillus subtilis and Clostridium species, to survive extreme environmental conditions. This process is tightly regulated by a series of signaling cascades and transcriptional controls, ensuring the formation of a highly resistant endospore.Sporulation is triggered by unfavorable conditions, such as nutrient depletion, and is governed by a phosphorelay system. One of the sensor kinases, such as...